KESIMPTA 20 mg in 0.4 mL Pen Injector
RxNorm 2390954
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2390954 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: KESIMPTA 20 mg in 0.4 mL Pen Injector.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
0.4 mL Kesimpta 50 mg/ML Pen Injector
(Atom ID: 12426247)
SBDPrescribable
Semantic Branded Drug (SBD):
0.4 mL ofatumumab 50 mg/ML Pen Injector [Kesimpta]
(Atom ID: 12426245)
PSNPrescribable
Prescribable Name (PSN):
KESIMPTA 20 mg in 0.4 mL Pen Injector
(Atom ID: 12426246)
SYPrescribable
Synonym (SY):
KESIMPTA 20 mg per 0.4 mL Sensoready Pen Injector
(Atom ID: 12426253)
Patient Education
Ofatumumab Injection
Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells) in adults who have not gotten better after treatment with fludarabine (Fludara) and alemtuzumab (Campath). Ofatumumab injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells.
[Learn More]
* Please review the disclaimer below.